FINNENCE ▪ THE WIRE FILE
THE WIRE · № 68991
News■ Unclear/unknown
MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-07 12:00 UTC
LAST UPDATE2026-10-07 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A 2.5-month survival extension in glioblastoma is modest and the company is not in the allowed ticker list.
Marginal efficacy gain in hard-to-treat cancer
CATALYST TO WATCH
Regulatory discussions or partnership
MAIN RISK
2.5-month benefit may not win approval
FULL DISPATCH
SurVaxM extended median overall survival by 2.5 months across the full trial population Statistical significance in overall survival benefit was achieved in patients aged 65 and under Findings are consistent with SurVaxM's immunotherapeutic mechanism and with results from the earlier...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting2026-10-07 12:00 UTC
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting2026-10-07 12:00 UTC
→CORRELATIONshares Healthcare
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds2026-10-07 12:02 UTC
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds2026-10-07 12:02 UTC
→CORRELATIONshares Healthcare
Where to Invest $100,000: Healthcare, AI and High-Quality Bonds2026-10-07 11:00 UTC
Where to Invest $100,000: Healthcare, AI and High-Quality Bonds2026-10-07 11:00 UTC
→CORRELATIONshares Healthcare
Manufacturing Bispecific Antibodies: Development & Scale-Up, Upcoming Webinar Hosted by Xtalks2026-10-07 12:30 UTC
Manufacturing Bispecific Antibodies: Development & Scale-Up, Upcoming Webinar Hosted by Xtalks2026-10-07 12:30 UTC
→CORRELATIONshares Healthcare
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body2026-10-07 12:30 UTC
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body2026-10-07 12:30 UTC
→CORRELATIONshares Healthcare
Why CVOTs Require a Different Approach: Optimizing Event Accrual to Reduce Trial Delays, Upcoming Webinar Hosted by Xtalks2026-10-07 12:30 UTC
Why CVOTs Require a Different Approach: Optimizing Event Accrual to Reduce Trial Delays, Upcoming Webinar Hosted by Xtalks2026-10-07 12:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.